Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by RAPT Therapeutics, Inc.

RAPT Therapeutics Reports Second Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports First Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers CTNM RAPT
RAPT Therapeutics Announces $150 Million Private Placement
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports First Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.